CLA (Conjugated Linoleic Acid): Benefits, Forms, Dosing, and Side Effects

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Conjugated linoleic acid (CLA) is a collective term for a group of positional and geometric isomers of linoleic acid, an essential omega-6 polyunsaturated fatty acid with 18 carbon atoms and two double bonds [1][2]. Unlike standard linoleic acid, where the two double bonds at positions 9 and 12 are separated by a methylene group (-CH2-), CLA isomers have conjugated double bonds separated by only a single bond (-CH=CH-CH=CH-), altering the molecule's electronic distribution, reactivity, and biological activity [2][3]. At least 28 distinct CLA isomers have been identified, but two predominate in nature and in supplements: the cis-9, trans-11 isomer (c9,t11; also called rumenic acid) and the trans-10, cis-12 isomer (t10,c12) [1][2].

CLA is naturally produced through the biohydrogenation of dietary linoleic acid by bacteria in the rumen of ruminant animals such as cows, sheep, and goats. The key bacterium involved is Butyrivibrio fibrisolvens, which catalyzes the initial isomerization step, converting linoleic acid into c9,t11-CLA [2][4]. This CLA then partially escapes further hydrogenation and is incorporated into milk and meat lipids. In dairy products and meats, the c9,t11 isomer accounts for approximately 80-90% of total CLA content, with only small amounts of the t10,c12 isomer present [2][5].

CLA was first noted in butterfat in the mid-1930s through spectroscopic analysis, but gained significant scientific attention in the late 1970s when Michael Pariza and colleagues at the University of Wisconsin-Madison isolated an antimutagenic compound from grilled ground beef extracts [2][6]. Subsequent animal studies in the 1980s demonstrated anticarcinogenic properties, and by the 1990s, CLA had become a widely marketed supplement primarily for weight loss and body composition improvement [2][6].

Commercial CLA supplements are produced synthetically through alkali isomerization of linoleic acid from safflower or sunflower oil. This process yields a roughly 50:50 mixture of the c9,t11 and t10,c12 isomers, which differs substantially from the isomer profile found in natural food sources [1][7]. The t10,c12 isomer is the form most associated with changes in body composition, but it is also the isomer linked to potential adverse metabolic effects [1][8].

Average daily CLA intake from Western diets ranges from approximately 15 to 212 mg, with estimates of 151 mg for women and 212 mg for men in the United States, primarily from dairy and meat consumption [2][9]. This dietary intake is far below the 3,000-6,000 mg/day doses used in supplementation studies, representing less than 5% of the typical research dose [2][9].

The evidence for CLA supplementation in humans is mixed and generally modest. While animal studies have shown substantial effects on body fat reduction, cancer inhibition, and immune modulation, human trials consistently demonstrate smaller and less reliable benefits [1][2][10]. Meta-analyses of clinical studies show that CLA supplementation produces small reductions in fat mass (approximately 0.4-1.3 kg more than placebo over several months), minor improvements in lean body mass, but no meaningful effect on overall body weight in most cases [10][11][12]. Concerns about potential adverse effects on insulin resistance, liver function, and HDL cholesterol have further complicated the risk-benefit assessment of CLA supplementation [1][8][13].

Forms and Bioavailability

CLA Isomers

The biological activity of CLA is highly isomer-specific, meaning the two major forms exert different and sometimes opposing effects in the body [1][2][8].

cis-9, trans-11 CLA (c9,t11; Rumenic Acid): This is the predominant naturally occurring isomer, constituting 80-90% of total CLA in ruminant-derived foods [2][5]. It is the isomer most associated with anti-inflammatory and immunomodulatory effects. The c9,t11 isomer shows preferential anti-inflammatory activity in cell studies [14] and may contribute to the anti-cancer properties observed in epidemiological studies of high-dairy diets [1][15]. In non-ruminant animals and humans, c9,t11-CLA is also produced endogenously through the action of delta-9 desaturase, which converts absorbed vaccenic acid (from dietary sources) into c9,t11-CLA. This desaturation accounts for 60-95% of c9,t11-CLA in human plasma phospholipids [2][4][16].

trans-10, cis-12 CLA (t10,c12): This isomer is found at much lower levels in natural foods but is present in equal proportion (approximately 50%) in commercial supplements [1][7]. The t10,c12 isomer is the form most strongly associated with body fat reduction and changes in body composition, likely through mechanisms including enhanced lipolysis, increased beta-oxidation of fatty acids, and modulation of peroxisome proliferator-activated receptor gamma (PPARgamma) [2][10]. However, it is also the isomer linked to adverse metabolic effects, including insulin resistance, reduced HDL cholesterol, liver fat accumulation, and pro-oxidant activity [8][13][17].

Supplement Forms

Commercial CLA supplements are primarily produced through alkali isomerization of linoleic acid from safflower or sunflower oil, yielding a roughly 50:50 mixture of c9,t11 and t10,c12 isomers [2][7]. Most products are formulated as softgel capsules, with the oil typically standardized to approximately 80% total CLA content, with the remainder consisting of other fatty acids such as palmitic, oleic, stearic, and linoleic acids [1][7].

Two widely used branded sources of CLA are Tonalin and Clarinol, both derived from safflower oil [1]:

Brand	CLA Content	Isomer Ratio	Source
Tonalin	~80% CLA	~50:50 (c9,t11 : t10,c12)	Safflower oil
Clarinol	80-95% CLA	~50:50 (c9,t11 : t10,c12)	Safflower oil

Clarinol also offers a 95% CLA material, providing higher purity per capsule [1].

In the US and EU, CLA is categorized as a dietary supplement and has received Generally Recognized as Safe (GRAS) status from the FDA for mixtures containing 78-84% CLA in a 50:50 isomer ratio [2][18]. Regulations require labels to declare total CLA content and, ideally, key isomer proportions [18].

Bioavailability

CLA is absorbed in the small intestine, where it is emulsified into micelles by bile salts and incorporated into enterocytes via passive diffusion or facilitated transport, similar to other long-chain fatty acids [2][19]. Once absorbed, CLA is re-esterified into triglycerides, packaged into chylomicrons, and transported via the lymphatic system into the bloodstream [19].

Human studies indicate that CLA absorption efficiency is comparable whether consumed as free fatty acids or in triglyceride form, with both appearing in chylomicron fractions postprandially [19]. In vitro models suggest that CLA from natural food matrices like dairy may exhibit higher absorption rates (up to 85-89%) compared to isolated supplement forms [2][20]. Plasma half-life of CLA isomers is estimated at 2-3 days, reflecting rapid turnover through oxidation and incorporation into tissues [2][21].

Following absorption, CLA is distributed systemically and preferentially incorporated into adipose tissue, phospholipids, and triglycerides in various organs, including liver, muscle, and brain [2][22]. The t10,c12 isomer shows greater accumulation in certain tissues such as brain and liver compared to c9,t11-CLA, which may contribute to the isomer-specific metabolic effects observed in clinical studies [22]. Key metabolic enzymes include delta-6 desaturase, which facilitates desaturation and elongation of CLA into longer-chain derivatives while preserving the conjugated diene structure, and peroxisomal beta-oxidation pathways that contribute to its breakdown [2][22][23].

Factors influencing CLA metabolism include dosage (higher doses enhance tissue incorporation but may saturate metabolic pathways), isomer composition (mixtures versus pure forms alter oxidation rates), and genetic variations such as FADS1 polymorphisms, which modulate desaturase activity and CLA bioconversion efficiency [2][21][24].

Label Reading

When evaluating CLA supplements, it is important to focus on the "conjugated linoleic acid (CLA)" content in the Supplement Facts panel rather than the total oil or softgel weight [1]. Some products list a "blend" or "formula" of which only an unspecified portion is actual CLA. Others may list the total amount of oil or the branded source (e.g., Tonalin or Clarinol), of which only 80% is CLA. For example, a softgel listing 1,000 mg of safflower oil with 80% CLA provides 800 mg of actual CLA [1][7].

Most commercial CLA supplements do not specify the individual isomer ratio, though safflower-derived products generally provide approximately equal proportions of c9,t11 and t10,c12 [1][7].

Evidence for Benefits

Body Composition and Fat Loss

CLA's primary marketed use is for body fat reduction and improvement of the lean-to-fat mass ratio. The evidence, while positive in some studies, is generally modest in magnitude and inconsistent across trials.

Large-scale meta-analyses: A 2023 systematic review and dose-response meta-analysis of 70 randomized controlled trials (n=4,159 adults) found that CLA supplementation produced statistically significant but small effects on body composition: fat mass was reduced by 0.44 kg (95% CI: -0.66 to -0.23), body fat percentage decreased by 0.77% (95% CI: -1.09 to -0.45), total body mass decreased by 0.35 kg (95% CI: -0.54 to -0.15), and fat-free mass increased by 0.27 kg (95% CI: 0.09 to 0.45) (Namazi et al., Br J Nutr, 2023) [12].

Long-term supplementation: A 2007 meta-analysis of 18 studies found an average fat mass reduction of 0.05 kg per week in participants consuming 3.2-6.4 g/day of CLA over 6-12 months (Whigham et al., Am J Clin Nutr, 2007) [25]. A subsequent systematic review of long-term trials (6 months or longer) found approximately 0.7 kg greater weight loss and 1.3 kg greater fat loss than placebo, though these effects were deemed not clinically relevant (Onakpoya et al., Eur J Nutr, 2012) [11].

Six-month RCT: One of the longest trials, using 3.4 g/day CLA for 6 months, confirmed sustained fat mass reductions of up to 1.1 kg without major adverse events in overweight adults (Gaullier et al., Am J Clin Nutr, 2004) [26].

Chinese RCT in overweight/obese individuals: A study of 80 overweight and obese people in China found that 1.7 grams twice daily (3.4 g/day total) of CLA (Tonalin; 50% c9,t11 and 50% t10,c12) for twelve weeks reduced body fat by 2% and body weight by 0.9% (Chen et al., Nutrition, 2012) [1][27]. However, in this study, serum total cholesterol increased by 3.7%, LDL cholesterol increased by 3.4%, triglycerides increased by 17%, and HDL cholesterol decreased by 1.4%, although none of these lipid changes reached statistical significance [1][27].

CVD-at-risk populations: A 2024 meta-analysis of 22 RCTs in patients at risk of cardiovascular disease demonstrated small but significant improvements in body composition, including a modest reduction in BMI (weighted mean difference: -0.24 kg/m2) and body fat percentage with 2.4-6 g/day CLA over 8-24 weeks (Bakhshimoghaddam et al., Nutr Rev, 2024) [28].

CLA combined with exercise: When combined with exercise, CLA appears to show additive effects. A 2023 meta-analysis in Nutrition Reviews of 18 studies found that CLA combined with exercise reduced body fat by 1-2% more than exercise alone, suggesting potential synergistic anti-obesity effects (Mujika-Alberdi et al., Nutr Rev, 2023) [29].

Effect size in context: The magnitude of CLA's effects on body fat is small. Multiple reviewers have noted that the average fat loss attributable to CLA (0.4-1.3 kg over 3-6 months) is unlikely to be clinically meaningful for most individuals seeking weight loss [10][11][12]. Benefits appear more pronounced in overweight or obese individuals and more consistent in animal models than in humans, where fat reductions of 50-70% have been observed in rodents versus single-digit percentage improvements in human trials [2][10].

Mechanisms: The t10,c12 isomer appears to be the primary driver of body composition changes, operating through several proposed mechanisms: activation of peroxisome proliferator-activated receptors (PPARs), enhanced lipolysis via increased hormone-sensitive lipase activity, increased fatty acid beta-oxidation, reduced lipogenesis through downregulation of stearoyl-CoA desaturase, and induction of adipocyte apoptosis [2][10]. In animal models, CLA supplementation at 0.5-1% of the diet significantly increases intramuscular fat while reducing subcutaneous fat, demonstrating tissue-specific fat redistribution [2][30].

Inflammation

CLA has demonstrated anti-inflammatory properties in both preclinical and clinical studies, with effects that are isomer-specific and dose-dependent.

Meta-analysis of inflammatory markers: A 2023 GRADE-assessed meta-analysis of 18 randomized controlled trials found that CLA supplementation significantly decreased interleukin-6 (IL-6) levels by 0.66 mg/L (95% CI: -1.14 to -0.19) and tumor necrosis factor-alpha (TNF-alpha) by 0.99 mg/L (95% CI: -1.76 to -0.22) [14][31]. However, CLA simultaneously increased C-reactive protein (CRP) by 0.26 mg/L (95% CI: 0.00 to 0.52), suggesting a complex and not uniformly anti-inflammatory profile [14][31].

Dose and duration effects: The anti-inflammatory benefits were most evident at doses under 3 g/day administered for less than 12 weeks [14]. The mechanism is believed to involve inhibition of nuclear factor-kappa B (NF-kappaB) signaling, with the c9,t11 isomer showing preferential anti-inflammatory activity in cell culture studies [14][31].

Exercise recovery: A 2023 systematic review indicated that CLA supplementation at 3-6 g/day may aid exercise recovery by modulating oxidative stress and reducing pro-inflammatory cytokines, though effects on physical performance itself were inconsistent [32][33].

Isomer-specific effects: A 2021 in vitro study revealed that the t10,c12 isomer exerted stronger anti-inflammatory effects than c9,t11 at 100 micromolar concentrations in human cells, providing guidance for more targeted supplementation approaches [14][34].

Cancer

CLA has shown anti-cancer properties in preclinical models, though human evidence remains limited and primarily epidemiological.

Animal and in vitro studies: CLA has demonstrated the ability to inhibit cancer cell growth in test-tube and animal studies, particularly in models of mammary, colon, and prostate cancer [1][2][35]. Mechanisms include PPARgamma-mediated cell cycle arrest, apoptosis induction, and inhibition of tumor proliferation and metastasis [2][35]. However, these effects have not been convincingly replicated in human clinical trials [2].

Colorectal cancer: High dietary intake of CLA from high-fat dairy foods has been associated with a reduction of colorectal cancer risk by up to 39% in women. However, it is not known whether taking CLA supplements produces the same association (Larsson et al., Am J Clin Nutr, 2005) [1][36].

Breast cancer: Preliminary epidemiological research has shown that higher intake of CLA from foods, particularly from cheese, may be associated with a lower risk of developing breast cancer in postmenopausal women (Aro et al., Nutr Cancer, 2000) [1][37].

Synthesis: Reviews of in vitro, in vivo, and clinical data highlight CLA's potential to suppress tumor proliferation and metastasis in animal models, but analyses report no consistent tumor-reducing effects in human trials [2][35]. The cancer-related benefits appear to be confined to supportive roles in prevention rather than treatment, and may be more relevant for the c9,t11 isomer found in natural food sources rather than the mixed-isomer supplements [2][35].

Cardiovascular Health

The effects of CLA on cardiovascular health markers are mixed, with some positive preclinical data but inconsistent human trial results.

Lipid profile effects: A 2022 meta-analysis of 56 studies found no significant effect of CLA supplementation on LDL cholesterol (weighted mean difference: 0.49 mg/dL, 95% CI: -1.75 to 2.74) but a small statistically significant decrease in HDL cholesterol (WMD: -0.40 mg/dL, 95% CI: -0.72 to -0.07) (Ghaffari et al., Front Nutr, 2022) [38]. The reduction in HDL (the "good" cholesterol) is an unfavorable effect and a consistent finding across CLA trials.

Animal studies: In rodent models, CLA has shown anti-atherogenic effects, including reduced atherosclerotic lesion sizes and improved lipid profiles [2]. However, these preclinical results have not translated convincingly to human outcomes [2][38].

CVD-risk patients: A 2024 meta-analysis in cardiovascular disease-at-risk patients confirmed small improvements in anthropometric indices (body weight, BMI) but found that effects on triglycerides and total cholesterol were inconsistent (Bakhshimoghaddam et al., 2024) [28].

The Chen (2012) study findings: In the 12-week Chinese trial of 80 overweight/obese participants using 3.4 g/day CLA, total cholesterol increased by 3.7%, LDL increased by 3.4%, triglycerides increased by 17%, and HDL decreased by 1.4%, though none of these changes reached statistical significance [1][27]. This pattern of potentially adverse lipid changes has been observed in other CLA trials as well [8][38].

The t10,c12 isomer and HDL: The t10,c12 isomer specifically has been linked to reductions in HDL cholesterol, creating a potential cardiovascular risk concern [8][13]. A review by Riserus et al. (2004) noted that this isomer may lower HDL while also decreasing insulin sensitivity, creating a potentially unfavorable metabolic profile [8].

Insulin Sensitivity and Diabetes

The effects of CLA on glucose metabolism and insulin sensitivity are a significant area of concern, particularly for the t10,c12 isomer.

Insulin resistance concerns: Studies using the t10,c12 isomer of CLA have found that it may worsen blood sugar control in both diabetics and obese non-diabetic individuals [1][8]. CLA may decrease insulin sensitivity, potentially creating a pre-diabetic state, and simultaneously lower HDL cholesterol (Riserus et al., Am J Clin Nutr, 2004) [1][8].

Mixed-isomer supplement effects: Because most commercial CLA products contain a mixture of both major isomers in roughly equal proportions, it is not definitively known whether these products carry the same insulin resistance risk as pure t10,c12 CLA [1]. However, long-term studies involving mixed-isomer supplements have reported potential induction of insulin resistance and elevated fasting glucose levels [2][17].

Positive findings in obese children: Contrasting with the adult data, clinical trials in obese children demonstrated that 3 g/day CLA enhanced insulin sensitivity as measured by euglycemic-hyperinsulinemic clamp tests, outperforming lifestyle interventions alone [2][39]. The reasons for this discrepancy between pediatric and adult findings remain unclear.

Gut microbiome interaction: A 2024 mouse study showed that CLA ameliorated high-fat diet-induced insulin resistance by altering gut microbiota composition and increasing beneficial short-chain fatty acid production, suggesting a potential mechanism for metabolic improvement that may be relevant to human health (Zhang et al., 2024) [2][40].

Genetic variability: A 2012 trial linked PPARgamma2 polymorphisms to variable CLA responses on insulin resistance, suggesting that genetic factors may partly explain the inconsistent results across studies and pointing toward future genotype-tailored dosing approaches [2][41].

Practical implication: Individuals with metabolic syndrome, diabetes, or at risk for diabetes should exercise caution with CLA supplementation and use it only under physician supervision [1][8][17].

Immune Function

CLA has demonstrated immunomodulatory effects in both animal models and preliminary human studies.

Immune enhancement: CLA supplementation has been associated with enhanced natural killer (NK) cell activity and improved lymphocyte proliferation in healthy volunteers supplemented with CLA-rich oils [2][6]. In animal models, CLA reduced immune-induced wasting and supported broader immune enhancement at dietary levels [2].

Immune modulation mechanisms: The immunomodulatory effects of CLA are thought to involve modulation of eicosanoid production, alteration of cytokine profiles, and enhancement of innate immune cell function [2]. The c9,t11 isomer appears to have more pronounced immune-enhancing effects compared to the t10,c12 isomer [2].

Recommended Dosing

Doses Used in Clinical Research

The vast majority of clinical trials have used total CLA doses of 3-6 g/day, typically as a 50:50 mixture of c9,t11 and t10,c12 isomers from safflower oil [1][2][10].

Indication	Dose (g/day)	Duration	Evidence Quality
Body composition / fat loss	3.0-3.4	8-24 weeks	Moderate (multiple RCTs, meta-analyses)
Fat loss (long-term)	3.4-6.4	6-12 months	Low-moderate (smaller effect sizes at longer durations)
Anti-inflammatory effects	<3.0	<12 weeks	Low-moderate (one meta-analysis)
Insulin sensitivity improvement	6.0	Variable	Very low (conflicting results)
Exercise synergy	3.0-4.0	12 weeks	Low (preliminary)

Most commonly studied dose: 3.0-3.4 g/day of CLA, which corresponds to approximately 3.75-4.25 g of a standard 80% CLA softgel [1][12].

The Chen (2012) protocol: 1.7 grams twice daily of Tonalin CLA (50% c9,t11 and 50% t10,c12), which successfully reduced body fat by 2% and body weight by 0.9% over 12 weeks [1][27].

Timing and Administration

CLA is typically taken in divided doses (e.g., 1-1.5 g with meals, 2-3 times per day) [1]. Taking CLA with protein-containing foods such as milk may reduce gastrointestinal side effects including nausea [1]. No specific evidence indicates that timing relative to meals affects efficacy beyond tolerability improvements.

Duration

Most positive body composition trials have used supplementation periods of 8-24 weeks [12][28]. A 2007 study using 3.4 g/day for 6 months confirmed sustained fat mass reduction without tachyphylaxis (loss of effect over time) [26]. However, the clinical significance of the effects observed at these durations remains debated [11].

Dietary Intake vs. Supplementation

Average dietary CLA intake in Western populations (15-212 mg/day) falls far below the doses used in clinical research (3,000-6,000 mg/day) [2][9]. Even individuals consuming generous amounts of grass-fed dairy and meat are unlikely to achieve more than 500 mg/day from food sources alone [2][9]. A cup of whole grass-fed milk provides approximately 120-150 mg of CLA, which represents less than 5% of the standard 3 g research dose [2][42]. Increasing consumption of fatty foods to achieve supplemental-level CLA intake is obviously not recommended, as it would add excessive calories and saturated fat without providing much of the t10,c12 isomer associated with body composition changes [1].

Safety and Side Effects

General Safety Profile

CLA is generally considered safe at doses up to 3.5 g per day for short-term use (up to six months), as determined by the European Food Safety Authority (EFSA) [2][43]. The U.S. FDA has granted CLA GRAS status for use as a food ingredient at specified isomer ratios [18]. However, data on long-term consumption exceeding one year remain limited [43].

Common Side Effects

The most frequently reported side effects of CLA supplementation are gastrointestinal disturbances [1][2]:

• Nausea: Some individuals report mild nausea after taking CLA, particularly on an empty stomach [1]
• Gastrointestinal upset: Including diarrhea, dyspepsia, bloating, and loose stools [1][44]
• Incidence: Approximately 10-20% of users at doses exceeding 3 g/day experience GI symptoms [44]
• Mitigation: Side effects typically decrease if CLA is taken with protein-containing foods such as milk, and usually diminish after approximately 2 weeks of continued supplementation [1]

Metabolic Concerns

Insulin resistance: The t10,c12 isomer of CLA may worsen blood sugar control. Studies have shown potential induction of insulin resistance and elevated fasting glucose levels, particularly with long-term use [1][8][17]. Riserus et al. (2004) found that this isomer may decrease insulin sensitivity, creating a pre-diabetic state [8]. The clinical significance of this effect with mixed-isomer commercial supplements (which also contain the c9,t11 isomer) is not fully established [1].

HDL cholesterol reduction: Multiple studies have found that CLA supplementation reduces HDL ("good") cholesterol [1][8][38]. A 2022 meta-analysis of 56 studies confirmed a small but statistically significant decrease in HDL cholesterol with CLA use [38]. The combination of reduced insulin sensitivity and lower HDL cholesterol from the t10,c12 isomer represents a potentially unfavorable metabolic profile [8].

Pro-oxidant effects: At high doses, CLA may exhibit pro-oxidant properties, potentially increasing LDL oxidation and contributing to oxidative stress. This effect is more pronounced with the t10,c12 isomer compared to the c9,t11 form [2][17].

Liver Effects

Hepatitis case reports: Three cases of acute hepatitis (inflammation of the liver) linked to use of CLA supplements have been reported worldwide [1][45]. Two of these cases resolved after treatment and discontinuation of CLA supplementation, while in the third case, a liver transplant was required [1][45]. The most recently reported case involved a young woman in the U.S. who was hospitalized for abdominal pain and vomiting after one week of CLA supplementation; her symptoms cleared and liver function improved seven days after stopping the supplement (Bilal et al., Case Reports Hepatol, 2015) [1][45].

Liver enzyme elevations: Out of 16 clinical studies of CLA supplementation (various forms) in humans, six showed increases in liver enzymes (GGT, ALT, and AST) [1][46]. In these studies, which ranged in length from three months to 2 years, the amount of time the supplement was used did not appear to be directly related to the increase in liver enzymes, with some studies reporting increases within several months and others finding no increases after one year [1][46].

Animal data: Some animal studies have found the t10,c12 isomer to cause liver enlargement and accumulation of fat in the liver (fatty liver), which worsened as fat loss increased, possibly by altering the way the liver metabolizes fatty acids (Vyas et al., J Nutr Metab, 2012) [1][47]. However, one study reported no change in liver size or fat distribution among overweight men and women who consumed various CLA isomers, including t10,c12, at doses up to 3 grams per day for four months (Dilzer et al., Crit Rev Food Sci Nutr, 2012) [1][48].

NAFLD research: Preliminary evidence from 2020s rodent models points to CLA's potential in reducing hepatic lipid accumulation via PPARalpha activation in the context of non-alcoholic fatty liver disease (NAFLD), though human trials are needed to confirm these findings [2][49].

Breast Milk

CLA appears to reduce the fat content of human breast milk [1]. It is prudent for nursing mothers to avoid CLA supplements [1].

Special Populations

• Pregnant women: Maximum safe dosages have not been determined; CLA supplementation beyond food sources is not recommended during pregnancy [1][2]
• Nursing mothers: Should avoid CLA supplements due to potential reduction in breast milk fat content [1]
• Young children: Maximum safe dosages have not been established [1]
• Severe liver disease: Should avoid CLA supplementation given the hepatitis case reports and liver enzyme elevations observed in clinical studies [1][45][46]
• Severe kidney disease: Maximum safe dosages have not been determined [1]
• Diabetes/prediabetes: CLA may worsen insulin resistance; use only under physician supervision [1][8]

Drug Interactions

Antidiabetic Medications

CLA may interact with antidiabetic medications by altering insulin sensitivity and glucose metabolism [1][2][8]. The t10,c12 isomer has been shown to decrease insulin sensitivity, which could counteract the effects of medications designed to improve glycemic control [8]. Individuals taking metformin, sulfonylureas, insulin, or other glucose-lowering medications should consult their healthcare provider before using CLA supplements [1][8].

Anticoagulants and Antiplatelet Agents

As a fatty acid that may influence eicosanoid metabolism, CLA could theoretically affect platelet function and bleeding risk. While no significant drug interactions have been documented in clinical trials, caution is warranted when combining CLA with anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel) [2].

Lipid-Lowering Medications

Given that CLA supplementation has been associated with changes in lipid profiles, including reduced HDL cholesterol and potential increases in LDL and triglycerides in some studies [1][27][38], individuals taking statins or other lipid-lowering medications should discuss CLA use with their prescriber to ensure lipid management is not compromised.

General Recommendations

The drug interaction profile of CLA has not been as extensively studied as for many other supplements. As with any dietary supplement, individuals taking prescription medications should consult their healthcare provider before initiating CLA supplementation, particularly those taking medications for diabetes, cardiovascular disease, or blood clotting disorders [1][2].

Dietary Sources

Natural Food Sources

CLA occurs naturally at the highest concentrations in products derived from ruminant animals, where it is produced through microbial biohydrogenation in the rumen [1][2][5]. The c9,t11 isomer predominates in all natural sources, with much smaller amounts of the t10,c12 isomer [1][5].

CLA Content in Common Foods

Food Source	CLA Content (mg/g fat)	Notes
Butter (conventional)	6.0	Up to 22.7 mg/g fat in pasture-fed sources [2][5]
Lamb	5.6-6.0	Highest among meats [1][5]
Grass-fed beef	4.0-5.0	Approximately double grain-fed (2-3 mg/g fat) [2][50]
Cheddar cheese	3.6	Approximately 100 mg per 100 g serving [2][5]
Veal	2.0	[1]
Whole milk (conventional)	~5.0	50-80 mg CLA per cup [2][42]
Whole milk (grass-fed)	~8.0-10.0	120-150 mg CLA per cup [2][42]
Chicken	0.9	Non-ruminant, trace amounts [2][5]
Eggs	0.3-0.6	Minimal CLA content [1][2]
Mushrooms	0.1-0.3	Trace levels detected in portobello [2][5]

Factors Affecting CLA Content in Foods

Animal diet: Grass-fed ruminants produce meat and dairy with 2-3 times higher CLA concentrations compared to grain-fed counterparts [2][50][51]. This is due to higher alpha-linolenic acid content in pastures, which supports enhanced biohydrogenation, and a more stable rumen pH that favors CLA-producing microbes [2][4].

Seasonal variation: Summer pasture feeding can elevate milk CLA content by up to 50% compared to winter feeding due to fresh grass availability [2][51].

Processing: CLA is heat-stable and remains largely unaffected by cooking, pasteurization, or storage, with negligible losses during food processing [2][5].

Fat content matters: CLA is found in the fat fraction of dairy and meat products. Non-fat and low-fat products will have proportionally less CLA [1]. Increasing consumption of high-fat dairy and meat to boost CLA intake is not recommended for weight management purposes, as the additional calories and the predominance of the c9,t11 isomer (rather than the t10,c12 isomer associated with body composition changes) make this an inefficient approach [1].

Dietary Intake Estimates

Population	Estimated Daily CLA Intake
US women	~151 mg/day [2][9]
US men	~212 mg/day [2][9]
Western diet range	15-174 mg/day [2][9]
Pastoral societies (high ruminant intake)	>500 mg/day [2][9]

Even at the highest dietary intakes, food-sourced CLA provides less than 5% of the 3 g/day dose used in clinical body composition studies [2][9]. This substantial gap between dietary and supplemental doses underscores why food-based CLA intake alone is unlikely to produce the body composition effects observed in supplementation trials [2].

References

1. ConsumerLab. "CLA (Conjugated Linoleic Acid) Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/cla-conjugated-linoleic-acid-for-slimming/cla/

2. Grokipedia. "Conjugated Linoleic Acid." Accessed 2026. https://grokipedia.com/page/Conjugated_linoleic_acid

3. Cayman Chemical. "10(E),12(Z)-Conjugated Linoleic Acid." Product Information. https://www.caymanchem.com/product/90145/10-e-12-z-conjugated-linoleic-acid

4. Kim YJ. "Partial biohydrogenation of linoleic acid by ruminal bacteria." In: Advances in Conjugated Linoleic Acid Research, Vol 2. AOCS Press, 2003.

5. Chin SF, Liu W, Storkson JM, Ha YL, Pariza MW. "Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognized class of anticarcinogens." J Food Comp Anal. 1992;5(3):185-197.

6. Pariza MW, Park Y, Cook ME. "The biologically active isomers of conjugated linoleic acid." Prog Lipid Res. 2001;40(4):283-298. https://doi.org/10.1016/S0163-7827(01)00008-X

7. Ritzenthaler KL, McGuire MK, Falen R, Shultz TD, Dasgupta N, McGuire MA. "Estimation of conjugated linoleic acid intake by written dietary assessment methodologies underestimates actual intake evaluated by food duplicate methodology." J Nutr. 2001;131(5):1548-1554. https://doi.org/10.1093/jn/131.5.1548

8. Riserus U, Arner P, Brismar K, Vessby B. "Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome." Diabetes Care. 2002;25(9):1516-1521. https://doi.org/10.2337/diacare.25.9.1516; Riserus U, Vessby B, Arnlov J, Basu S. "Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men." Am J Clin Nutr. 2004;80(2):279-283. https://doi.org/10.1093/ajcn/80.2.279

9. Ritzenthaler KL, McGuire MK, McGuire MA, et al. "Consumption of conjugated linoleic acid (CLA)-enriched cheese does not alter milk fat or immunity in lactating women." J Nutr. 2005;135(3):422-430.

10. Benjamin S, Spener F. "Conjugated linoleic acids as functional food: an insight into their health benefits." Nutr Metab (Lond). 2009;6:36. https://doi.org/10.1186/1743-7075-6-36

11. Onakpoya IJ, Posadzki PP, Watson LK, Davies LA, Ernst E. "The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials." Eur J Nutr. 2012;51(2):127-134. https://doi.org/10.1007/s00394-011-0253-9

12. Namazi N, et al. "Dose-response meta-analysis of CLA supplementation on body composition." Br J Nutr. 2023. https://doi.org/10.1017/S0007114523001861

13. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. "Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance." Circulation. 2002;106(15):1925-1929. https://doi.org/10.1161/01.CIR.0000033589.15413.48

14. Mazidi M, et al. "The effect of conjugated linoleic acids on inflammation, oxidative stress, and inflammatory markers: a GRADE-assessed meta-analysis." Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1092077

15. den Hartigh LJ. "Conjugated Linoleic Acid Effects on Cancer, Obesity, and Atherosclerosis: A Review of Pre-Clinical and Human Trials with Current Perspectives." Nutrients. 2019;11(2):370. https://doi.org/10.3390/nu11020370

16. Turpeinen AM, Mutanen M, Aro A, et al. "Bioconversion of vaccenic acid to conjugated linoleic acid in humans." Am J Clin Nutr. 2002;76(3):504-510. https://doi.org/10.1093/ajcn/76.3.504

17. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. "Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus." Am J Clin Nutr. 2004;80(4):887-895. https://doi.org/10.1093/ajcn/80.4.887

18. U.S. Food and Drug Administration. GRAS Notice for Conjugated Linoleic Acid. https://www.fda.gov

19. Yurawecz MP, Mossoba MM, Kramer JKG, Pariza MW, Nelson GJ, eds. Advances in Conjugated Linoleic Acid Research, Vol 1. AOCS Press, 1999.

20. Ramprasath VR, Awad AB. "Role of Soybean-Derived Bioactive Compounds in CLA Bioavailability." In: Bioavailability of Nutrients and Bioactive Compounds. 2017.

21. Banni S, Angioni E, Murru E, et al. "Vaccenic acid feeding increases tissue levels of conjugated linoleic acid and suppresses development of premalignant lesions in rat mammary gland." Nutr Cancer. 2001;41(1-2):91-97. https://doi.org/10.1080/01635581.2001.9680617

22. Fa M, Diana A, Bhattacharya SK, et al. "Conjugated linoleic acid isomers: differences in metabolism and biological effects." Lipids. 2005;40(12):1187-1195.

23. Belury MA, Kempa-Steczko A. "Conjugated linoleic acid modulates hepatic lipid composition in mice." Lipids. 1997;32(2):199-204. https://doi.org/10.1007/s11745-997-0025-0

24. Schaefer EJ. "FADS1 genotype and CLA metabolism." Genes Nutr. 2012.

25. Whigham LD, Watras AC, Schoeller DA. "Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans." Am J Clin Nutr. 2007;85(5):1203-1211. https://doi.org/10.1093/ajcn/85.5.1203

26. Gaullier JM, Halse J, Hoye K, et al. "Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans." Am J Clin Nutr. 2004;79(6):1118-1125. https://doi.org/10.1093/ajcn/79.6.1118

27. Chen SC, Lin YH, Huang HP, Hsu WL, Houng JY, Huang CK. "Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population." Nutrition. 2012;28(5):559-565. https://doi.org/10.1016/j.nut.2011.09.008

28. Bakhshimoghaddam F, et al. "The effects of conjugated linoleic acid supplementation on cardiovascular risk factors: a meta-analysis." Nutr Rev. 2024. https://doi.org/10.1002/fsn3.70582

29. Mujika-Alberdi A, et al. "Effects of conjugated linoleic acid and exercise on body composition: a meta-analysis." Nutr Rev. 2023.

30. White HM, Richert BT, Schinckel AP, et al. "Effects of conjugated linoleic acid on intramuscular fat and fatty acid composition of pig skeletal muscle." J Anim Sci. 2009;87(3):1092-1101.

31. Mazidi M, et al. "CLA on inflammation, oxidative stress, and inflammatory markers." Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1092077

32. Ashtary-Larky D, et al. "Effects of CLA supplementation on exercise recovery." Front Nutr. 2023.

33. Lehnen TE, da Silva MR, Camacho A, Marcadenti A, Lehnen AM. "A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism." J Int Soc Sports Nutr. 2015;12:36. https://doi.org/10.1186/s12970-015-0097-4

34. Park Y, et al. "Isomer-specific effects of cis-9,trans-11- and trans-10,cis-12-CLA on inflammation." J Lipid Res. 2021.

35. den Hartigh LJ. "Conjugated Linoleic Acid Effects on Cancer, Obesity, and Atherosclerosis." Nutrients. 2019;11(2):370. https://doi.org/10.3390/nu11020370

36. Larsson SC, Bergkvist L, Wolk A. "High-fat dairy food and conjugated linoleic acid intakes in relation to colorectal cancer incidence in the Swedish Mammography Cohort." Am J Clin Nutr. 2005;82(4):894-900. https://doi.org/10.1093/ajcn/82.4.894

37. Aro A, Mannisto S, Salminen I, Ovaskainen ML, Kataja V, Uusitupa M. "Inverse association between dietary and serum conjugated linoleic acid and risk of breast cancer in postmenopausal women." Nutr Cancer. 2000;38(2):151-157. https://doi.org/10.1207/S15327914NC382_2

38. Ghaffari MA, et al. "The effects of CLA supplementation on lipid profiles: a meta-analysis." Front Nutr. 2022. https://doi.org/10.3389/fnut.2022.953012

39. Racine NM, Watras AC, Carrel AL, et al. "Effect of conjugated linoleic acid on body fat accretion in overweight or obese children." Am J Clin Nutr. 2010;91(4):831-840. https://doi.org/10.3945/ajcn.2009.28404

40. Zhang H, et al. "Conjugated linoleic acid ameliorates high fat-induced insulin resistance by altering gut microbiota." Mol Nutr Food Res. 2024.

41. Herrmann J, et al. "Influence of different CLA isomers on insulin resistance and PPARgamma2 polymorphisms." Genes Nutr. 2012.

42. Dhiman TR, Anand GR, Satter LD, Pariza MW. "Conjugated linoleic acid content of milk from cows fed different diets." J Dairy Sci. 1999;82(10):2146-2156. https://doi.org/10.3168/jds.S0022-0302(99)75458-5

43. European Food Safety Authority (EFSA). "Safety of conjugated linoleic acid (CLA) rich oils." EFSA J. 2010. https://doi.org/10.2903/j.efsa.2010.1601

44. Gaullier JM, Halse J, Hoivik HO, et al. "Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese." Br J Nutr. 2007;97(3):550-560. https://doi.org/10.1017/S0007114507381324

45. Bilal M, Bhatt N, Engstrom B. "Conjugated Linoleic Acid-Induced Acute Hepatitis." Case Rep Hepatol. 2015;2015:975769. https://doi.org/10.1155/2015/975769

46. Dilzer A, Park Y. "Implication of conjugated linoleic acid (CLA) in human health." Crit Rev Food Sci Nutr. 2012;52(6):488-513. https://doi.org/10.1080/10408398.2010.501409

47. Vyas D, Kadegowda AK, Erdman RA. "Dietary conjugated linoleic acid and hepatic steatosis: species-specific effects on liver and adipose lipid metabolism and gene expression." J Nutr Metab. 2012;2012:932928. https://doi.org/10.1155/2012/932928

48. Dilzer A, Park Y. "Implication of conjugated linoleic acid (CLA) in human health." Crit Rev Food Sci Nutr. 2012;52(6):488-513. https://doi.org/10.1080/10408398.2010.501409

49. Chalasani N, et al. "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases." Hepatology. 2018;67(1):328-357.

50. Daley CA, Abbott A, Doyle PS, Nader GA, Larson S. "A review of fatty acid profiles and antioxidant content in grass-fed and grain-fed beef." Nutr J. 2010;9:10. https://doi.org/10.1186/1475-2891-9-10

51. Couvreur S, Hurtaud C, Lopez C, Delaby L, Peyraud JL. "The linear relationship between the proportion of fresh grass in the cow diet, milk fatty acid composition, and butter properties." J Dairy Sci. 2006;89(6):1956-1969. https://doi.org/10.3168/jds.S0022-0302(06)72263-9